Oncology Brothers: Practice-Changing Cancer Discussions Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
May 15, 2025
This discussion features Dr. Susan Scott, a thoracic medical oncologist from Johns Hopkins, who specializes in lung cancer treatment. She delves into the latest options for metastatic non-small cell lung cancer, such as osimertinib and various chemotherapy combinations. The significance of comprehensive NGS testing and adjusting treatment plans based on patient responses is emphasized. Scott also provides insights into managing side effects and the role of immunotherapy in treatment, highlighting the importance of patient choices in their care.
AI Snips
Chapters
Transcript
Episode notes
EGFR Mutation Frontline Therapy Options
- Frontline EGFR mutation treatment now has multiple effective options beyond osimertinib monotherapy.
- Amivantamab plus lazertinib shows promising overall survival benefits but comes with distinct side effects to manage.
Managing Amivantamab Skin Toxicity
- Proactively manage amivantamab-associated cutaneous toxicity using doxycycline, chlorhexidine, and ceramide lotion.
- Advise sun avoidance to reduce severity of skin side effects.
Importance of Repeat NGS Testing
- Always repeat NGS testing at progression to detect resistance mutations or small cell transformation.
- Adjust treatment based on new findings to optimize sequencing of therapies.